Eton Pharmaceuticals has announced the relaunch of HEMANGEOL.

“We are excited to deliver another major product launch for the company. HEMANGEOL is a critical and time-sensitive therapy where early treatment can meaningfully impact outcomes, and the only FDA-approved treatment for infantile hemangiomas. With the integration of Eton Cares and a dedicated rare disease specialty pharmacy model, we are focused on helping patients start therapy quickly and ensuring families are supported from prescription through treatment. Our HEMANGEOL commercial team has been actively working with caregivers, healthcare professionals, and pharmacies to ensure a seamless transition for patients,” said Sean Brynjelsen, CEO, Eton Pharmaceuticals.

HEMANGEOL is an orphan drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. Infantile hemangiomas are non-cancerous vascular tumors which typically appear in the first days or weeks of a newborn’s life. In severe cases, infantile hemangiomas can lead to more serious complications, and require intervention with systemic therapy. Treatment with HEMANGEOL is typically initiated between five weeks to five months of age, and continues for approximately six months, representing a critical window where timely intervention can prevent complications and improve outcomes. It is estimated that approximately 5,000-10,000 infants are treated with HEMANGEOL annually in the US.

Dr. Maria Gnarra Buethe, MD, PhD, Division Chief of Dermatology, Rady Children’s Hospital of Orange County and Director of Pediatric Dermatology, University of California, Irvine, said, “Infantile hemangiomas can evolve rapidly, and timely intervention is critical. In practice, the challenge is often not recognising when to treat but ensuring that infants can start therapy without delays. Streamlined access to an FDA-approved treatment designed specifically for this population can meaningfully improve both outcomes and the care experience for families.”